Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

SNGXSoligenixFinished

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

3Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • A key executive is leaving

    Since Jun 12, 2026 · was worth 15, fading over time

    +2.7
Worry score3

Score over time

Stage
Phase 2
Patients
10 (final count)
Started
Dec 5, 2023
Main results expected
May 31, 2024
Fully finished
Jun 27, 2024
Results posted
Aug 20, 2025

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score

    Measured over: 12 weeks

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • key_exec_departure: base 15, now 2.7, since 2026-06-12, fades (half-life) · source filing

Raw record changes

  • none yet

Trial ID NCT06149247 · record last updated 2025-08-20 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06149247) ↗